Alopecia Areata Case Highlights Facial Loss and JAK Screening

A 42-year-old man with a three-year history of alopecia areata developed 85% hair loss over eight weeks after an 18-month stable period, with new eyebrow and beard involvement. Dr. Ungar presents the patient as Case 3 in a single-patient clinical vignette about severity assessment and preparation for JAK inhibitor treatment, rather than a comparative trial.

The man withdrew from the gym and video calls after the flare and said he felt “unrecognizable.” He gained little from six months of a high-potency topical corticosteroid plus topical minoxidil, despite both treatments. His three-year history included the 18-month stable interval before the eight-week progression.

Dr. Ungar said this late flare is common in his practice: patients with “mild, stable, locally treated disease” can worsen after years. He uses the patient’s account of feeling “unrecognizable” to underline the effect on self-identity, rather than treating hair quantity as the only measure of severity.

How does facial involvement change severity?

Dr. Ungar said the impact of facial hair loss is not proportional to the amount lost, especially on the face. Small beard patches or partial eyebrow or eyelash loss can weigh heavily, he said, even when scalp loss appears less extensive. Facial involvement therefore changes the severity assessment in a way a scalp-only percentage does not capture.

In Dr. Ungar’s view, a patient with 35% to 40% scalp loss plus facial involvement still has severe alopecia areata. The case patient had 85% hair loss with new eyebrow and beard involvement.

The vignette still makes the same clinical point: limited facial hair loss can disrupt identity and daily activity. His withdrawal from the gym and video calls gives that disruption a concrete measure.

The case does not provide a formal quality-of-life score, and Dr. Ungar did not assign one. Instead, he describes the burden directly through the patient’s “unrecognizable” description and the behavioral changes accompanying the eight-week flare. That keeps the assessment anchored in observed function rather than an unquantified severity label.

What does Dr. Ungar test before a JAK inhibitor?

Dr. Ungar follows the label nuances for each JAK inhibitor but orders one broad baseline set for the agents discussed in the case. His workup includes:

• tuberculosis testing;
• hepatitis virus testing;
• a complete blood count, or CBC;
• a complete metabolic panel, or CMP; and
• a lipid panel.

He checks thyroid function only when he has a reason to do so, rather than adding it routinely to the panel. Dr. Ungar also discusses herpes zoster vaccination and avoiding live vaccines in the pre-treatment workup.

For deuruxolitinib, Dr. Ungar adds CYP2C9 testing. A person with two copies of the relevant variant may be a poor metabolizer and may not be a candidate for that drug, which Dr. Ungar said is uncommon. This genotype finding adds a drug-specific step to the broader workup.

He orders CYP2C9 testing alongside the QuantiFERON test, and results typically return within several days. The preview does not specify a start date, dose or interval for the JAK inhibitor under consideration, so it does not establish when therapy would begin. Its documented focus is the baseline workup: the broad panel, conditional thyroid testing, vaccine discussion and deuruxolitinib-specific genotype result.

What will the longer session examine?

Dr. Ungar’s planned session, “JAK Inhibitors in Alopecia Areata: Treatment Goals, Safety Data, and Long-Term Management,” will address treatment goals, safety evidence and long-term management. The case supplies the assessment context for that discussion.

It does not report a drug-specific efficacy endpoint, adverse-event rate, dosing regimen or response duration, and it should not be read as a comparison among JAK inhibitors. The case therefore supports a workup and severity framework, not a drug ranking.

The case sets a concrete sequence. Dr. Ungar documents the three-year history, the 18-month stable interval, the eight-week progression and the 85% loss; weighs facial involvement beyond hair counts; and reviews the six-month topical course.

Testing follows the JAK inhibitor under consideration, with deuruxolitinib adding the CYP2C9 step. Dr. Ungar’s forthcoming session will connect those immediate decisions with safety evidence, treatment goals and long-term management.